Quanterix Corporation
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG0027NWC69
QTRX
Quanterix Corporation
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Medical Devices
NAME
Quanterix Corporation
ISIN
US74766Q1013
TICKER
QTRX
MIC
XNAS
REUTERS
QTRX.OQ
BLOOMBERG
QTRX US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Do., 14.11.2024
Quanterix
US74766Q1013
Law Offices of Howard G. Smith announces an investigation on behalf of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX) investors concerning the Company’s possible violations of federal securities laws.
On November 12, 2024, after market hours, Quanterix disclosed that it had “identified an error related to the capitalization ...
Quanterix
Do., 14.11.2024
Quanterix
US74766Q1013
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation (“Quanterix” or “the Company”) (NASDAQ: QTRX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed...
Quanterix
Do., 14.11.2024
Quanterix
US74766Q1013
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX) investors concerning the Company’s possible violations of the federal securities laws.
If you suffered a loss on your Quan...
Quanterix
Mi., 13.11.2024
Quanterix
US74766Q1013
The Law Offices of Frank R. Cruz announces an investigation of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ:QTRX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On November 12, 2024, after market hours, Quan...
Quanterix
Di., 12.11.2024
Quanterix
US74766Q1013
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced preliminary financial results for the third quarter ended September 30, 2024 and reaffirmed its full year 2024 guidance. The Company also disclosed the need to restate certain prior period financial statements t...
Quanterix
Di., 05.11.2024
Quanterix
US74766Q1013
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Tuesday, November 12, 2024, at 4:30 p.m. E.T., to discuss third quarter 2024 financial results.
Quanterix will issue a press release regarding third quarter 2024 financial ...
Quanterix
Mo., 28.10.2024
Quanterix
US74766Q1013
Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer’s Disease (AD) in a broader range of patients.
Recent Alzheimer’s Association criteria for diagnosing Alzheimer’s recommend that plasma p-Tau 217 tests be designed with two cutoffs ...
Quanterix
Mi., 02.10.2024
Quanterix
US74766Q1013
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors.
Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, inclu...
Quanterix
Mo., 30.09.2024
Quanterix
US74766Q1013
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it is making its Simoa® p-Tau 217 Planar Kit commercially available as part of the next phase of Alzheimer’s Disease (AD) test development. The kit uses p-Tau 217 antibody technology ...
Quanterix
Do., 29.08.2024
Quanterix
US74766Q1013
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will take part in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 at 1:50 ...
Quanterix
Informationen zu Product Placements
